含贝达奎林的个体方案对耐药结核病患者的早期疗效

IF 1.9 4区 医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
O. Putra, Yulistiani Yulistiani, S. Soedarsono, Susi Subay
{"title":"含贝达奎林的个体方案对耐药结核病患者的早期疗效","authors":"O. Putra, Yulistiani Yulistiani, S. Soedarsono, Susi Subay","doi":"10.4103/1995-7645.372289","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate early efficacy of sputum conversion within 6 months of individual regimens containing bedaquiline in patients with drug resistant tuberculosis. Methods: We conducted a retrospective study among patients with drug resistant tuberculosis who were receiving individual regimens containing bedaquiline. The primary outcome was sputum conversion of both smear and culture within 6 months of treatment. We used medical records of drug resistant tuberculosis patients from January 2020 to December 2021. The study was conducted at Dr. Soetomo Hospital, Indonesia from August to October 2022. Results: In this study, 44 eligible drug resistant tuberculosis patients were initiated on regimens containing bedaquiline. There were 52.3% males and the median age was 45.5 years. The rates of previous treatment (70.5%) and lung cavity (36.4%) were high. The most common companion drugs included clofazimine, cycloserine, levofloxacin, and linezolid. Sputum smear and culture conversion was seen in 79.4% and 82.1% at the 2nd month, respectively. More than 97% patients had smear and culture conversion at the end of 6 months. Conclusions: Among drug resistant tuberculosis patients, individual regimens containing bedaquiline were associated with high rates of smear and culture conversion at the end of 6 months. Early efficacy of regimens containing bedaquiline can be used to predict cure rate at the end of treatment.","PeriodicalId":8559,"journal":{"name":"Asian Pacific journal of tropical medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis\",\"authors\":\"O. Putra, Yulistiani Yulistiani, S. Soedarsono, Susi Subay\",\"doi\":\"10.4103/1995-7645.372289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To evaluate early efficacy of sputum conversion within 6 months of individual regimens containing bedaquiline in patients with drug resistant tuberculosis. Methods: We conducted a retrospective study among patients with drug resistant tuberculosis who were receiving individual regimens containing bedaquiline. The primary outcome was sputum conversion of both smear and culture within 6 months of treatment. We used medical records of drug resistant tuberculosis patients from January 2020 to December 2021. The study was conducted at Dr. Soetomo Hospital, Indonesia from August to October 2022. Results: In this study, 44 eligible drug resistant tuberculosis patients were initiated on regimens containing bedaquiline. There were 52.3% males and the median age was 45.5 years. The rates of previous treatment (70.5%) and lung cavity (36.4%) were high. The most common companion drugs included clofazimine, cycloserine, levofloxacin, and linezolid. Sputum smear and culture conversion was seen in 79.4% and 82.1% at the 2nd month, respectively. More than 97% patients had smear and culture conversion at the end of 6 months. Conclusions: Among drug resistant tuberculosis patients, individual regimens containing bedaquiline were associated with high rates of smear and culture conversion at the end of 6 months. Early efficacy of regimens containing bedaquiline can be used to predict cure rate at the end of treatment.\",\"PeriodicalId\":8559,\"journal\":{\"name\":\"Asian Pacific journal of tropical medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Pacific journal of tropical medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/1995-7645.372289\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of tropical medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/1995-7645.372289","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价含贝达奎林的个体方案治疗耐药肺结核6个月内转痰的早期疗效。方法:我们对接受含贝达奎林的个体治疗方案的耐药结核病患者进行了回顾性研究。主要结果是在治疗后6个月内,痰涂片和培养物均得到转化。我们使用了2020年1月至2021年12月耐药结核病患者的病历。该研究于2022年8月至10月在印度尼西亚Soetomo医生医院进行。结果:在本研究中,44名符合条件的耐药结核病患者开始接受含有贝达奎林的方案。男性52.3%,中位年龄45.5岁。既往治疗的发生率(70.5%)和肺空洞发生率(36.4%)较高。最常见的配套药物包括氯法齐明、环丝氨酸、左氧氟沙星和利奈唑胺。第2个月痰涂片和培养物转化率分别为79.4%和82.1%。超过97%的患者在6个月结束时进行了涂片和培养转化。结论:在耐药结核病患者中,含贝达奎林的个体方案与6个月底的高涂片和培养转化率相关。含有贝达奎林的方案的早期疗效可用于预测治疗结束时的治愈率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis
Objective: To evaluate early efficacy of sputum conversion within 6 months of individual regimens containing bedaquiline in patients with drug resistant tuberculosis. Methods: We conducted a retrospective study among patients with drug resistant tuberculosis who were receiving individual regimens containing bedaquiline. The primary outcome was sputum conversion of both smear and culture within 6 months of treatment. We used medical records of drug resistant tuberculosis patients from January 2020 to December 2021. The study was conducted at Dr. Soetomo Hospital, Indonesia from August to October 2022. Results: In this study, 44 eligible drug resistant tuberculosis patients were initiated on regimens containing bedaquiline. There were 52.3% males and the median age was 45.5 years. The rates of previous treatment (70.5%) and lung cavity (36.4%) were high. The most common companion drugs included clofazimine, cycloserine, levofloxacin, and linezolid. Sputum smear and culture conversion was seen in 79.4% and 82.1% at the 2nd month, respectively. More than 97% patients had smear and culture conversion at the end of 6 months. Conclusions: Among drug resistant tuberculosis patients, individual regimens containing bedaquiline were associated with high rates of smear and culture conversion at the end of 6 months. Early efficacy of regimens containing bedaquiline can be used to predict cure rate at the end of treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Asian Pacific journal of tropical medicine
Asian Pacific journal of tropical medicine PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-TROPICAL MEDICINE
CiteScore
4.00
自引率
9.70%
发文量
1936
审稿时长
3-8 weeks
期刊介绍: Asian Pacific Journal of Tropical Medicine (ISSN 1995-7645 CODEN: APJTB6), a publication of Editorial office of Hainan Medical University,is a peer-reviewed print + online Monthly journal. The journal''s full text is available online at http://www.apjtm.org/. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. APJTM aims to provide an academic communicating platform for international physicians, medical scientists, allied health scientists and public health workers, especially those of the Asia-Pacific region and worldwide on tropical medicine, infectious diseases and public health, and to meet the growing challenges of understanding, preventing and controlling the dramatic global emergence and re-emergence of infectious diseases in the Asia-Pacific. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on tropical medicine, infectious diseases and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. The APJTM will allow us to seek opportunities to work with others who share our aim, and to enhance our work through partnership, and to uphold the standards of our profession and contribute to its advancement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信